It was a bumper year for the medicinal mammoth Novo Nordisk. The company has posted a pre-tax profit of 34.5 billion kroner off revenue of 88.8 billion kroner – an increase in turnover of 8 percent on 2013.
Jyllands-Posten calculates that this equates to earning 4 million kroner per hour, day and night over the whole year.
An important year in 2015
Lars Rebien Sørensen, the head of Novo Nordisk, expressed satisfaction this morning. "We are pleased with Novo Nordisk's financial performance in 2014 – a more challenging year than usual,” he said.
“Levemir and Victoza drove most of our sales growth, and our new long-acting insulin Tresiba continues to perform well. 2015 will be an important year for us with the first launches of Saxenda and Xultophy as well as significant results from our late-stage development portfolio."
The US dollar exchange rate contributed to a favourable price development for the company, with sales in North America up 11 percent.
Progress in America is set to continue following the FDA approval of the obesity drug Saxenda in September.
